SG Americas Securities LLC has $49,000 position in Precigen, Inc. (NASDAQ:PGEN)

SG Americas Securities LLC reduced its stake in Precigen, Inc. (NASDAQ:PGEN – Free Report) by 39.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,240 shares of the biotechnology company’s stock after selling 20,529 shares during the quarter. SG Americas Securities LLC’s holdings in Precigen were worth $49,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently modified their holdings of the company. Fortis Group Advisors LLC bought a new stake in shares of Precigen in the first quarter valued at approximately $28,000. EntryPoint Capital LLC bought a new position in Precigen in the first quarter valued at $31,000. Fisher Asset Management LLC purchased a new stake in shares of Precigen in the 4th quarter valued at $29,000. Simplicity Wealth LLC bought a new stake in shares of Precigen in the first quarter worth $51,000. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Precigen by 66.1% in the first quarter. China Universal Asset Management Co. Ltd. now owns 47,829 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 19,041 shares in the last quarter. 33.51% of shares are owned by institutional investors.

Precigen stock performance

Precigen stock opened at $1.15 on Wednesday. The firm has a market cap of $290.67 million, a P/E ratio of -2.95 and a beta of 1.73. The company has a 50-day moving average of $1.44 and a 200-day moving average of $1.45. Precigen, Inc. has a 1 year low of $0.84 and a 1 year high of $1.93.

Insider buying and selling

In other news, SVP Jeffrey Thomas Perez bought 58,823 shares of the stock in a transaction on Friday, August 9th. The shares were purchased at an average price of $0.85 per share, with a total value of $49,999.55. Following the completion of the purchase, the senior vice president now owns 743,097 shares of the company’s stock, valued at $631,632.45. The acquisition was disclosed in a filing with the SEC, which is accessible via this hyperlink. 44.90% of shares are owned by insiders.

The Wall Street analyst weighs in

A number of analysts recently commented on the company. JMP Securities reduced their price objective on Precigen from $14.00 to $7.00 and set a “market outperform” rating for the company in a research report on Thursday, August 15th. HC Wainwright lowered their target price on shares of Precigen from $6.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, August 15th. Stifel Nicolaus upped their target price on shares of Precigen from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, June 3rd. Cantor Fitzgerald restated an “overweight” rating on shares of Precigen in a research note on Wednesday, May 15th. Finally, StockNews.com raised shares of Precigen to a “sell” rating in a report on Thursday, August 1st. Two analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $7.00, based on data from MarketBeat.com.

Check out our latest research report on Precigen

About Precigen

(Free Report)

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies using precision technology to target diseases in the therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.

Further reading

Want to see what other hedge funds own PGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Precigen, Inc. (NASDAQ:PGEN – Free Report).

Get news and reviews for Precigen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Precigen and related companies with MarketBeat.com’s FREE daily email newsletter.